Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Orthopediatrics (KIDS) Net Income towards Common Stockholders (2016 - 2026)

Orthopediatrics has reported Net Income towards Common Stockholders over the past 11 years, most recently at -$10.7 million for Q1 2026.

  • For Q1 2026, Net Income towards Common Stockholders changed 0.26% year-over-year to -$10.7 million; the TTM value through Mar 2026 reached -$39.7 million, up 2.46%, while the annual FY2025 figure was -$39.6 million, 4.83% down from the prior year.
  • Net Income towards Common Stockholders for Q1 2026 was -$10.7 million at Orthopediatrics, down from -$10.1 million in the prior quarter.
  • Over five years, Net Income towards Common Stockholders peaked at $18.5 million in Q3 2022 and troughed at -$16.1 million in Q4 2024.
  • A 5-year average of -$6.3 million and a median of -$7.8 million in 2024 define the central range for Net Income towards Common Stockholders.
  • On a YoY basis, Net Income towards Common Stockholders climbed as much as 943.83% in 2022 and fell as far as 11000.0% in 2022.
  • Year by year, Net Income towards Common Stockholders stood at -$7.8 million in 2022, then rose by 14.74% to -$6.7 million in 2023, then tumbled by 140.16% to -$16.1 million in 2024, then soared by 37.13% to -$10.1 million in 2025, then decreased by 5.78% to -$10.7 million in 2026.
  • Business Quant data shows Net Income towards Common Stockholders for KIDS at -$10.7 million in Q1 2026, -$10.1 million in Q4 2025, and -$11.8 million in Q3 2025.